The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
SOFT And TEXT Premenopausal Randomised Adjuvant Endocrine Breast Cancer Trials.
Funder
National Health and Medical Research Council
Funding Amount
$722,380.00
Summary
SOFT and TEXT trials enrolled premenopausal women with hormone-sensitive early breast cancer to assess if post-operative hormone treatment that included ovarian function suppression plus tamoxifen, or an aromatase inhibitor exemestane, could improve outcomes. Initial results indicate fewer breast cancer recurrences with the treatment combination of ovarian suppression plus exemestane as compared with tamoxifen, and follow-up of women in these trials can show if overall survival can be improved.
Molecular hallmarks of androgen receptor targeting in prostate cancer. There is a critical need in oncology drug development for better biomarkers of response to prostate cancer therapies, clinically to assist with treatment decision making, and pre-clinically to facilitate translation of emerging agents into clinical practice. Using a unique explant culture model, this project will identify protein and lipid markers that can be used to accurately and reliably assess response to androgen recepto ....Molecular hallmarks of androgen receptor targeting in prostate cancer. There is a critical need in oncology drug development for better biomarkers of response to prostate cancer therapies, clinically to assist with treatment decision making, and pre-clinically to facilitate translation of emerging agents into clinical practice. Using a unique explant culture model, this project will identify protein and lipid markers that can be used to accurately and reliably assess response to androgen receptor (AR)-targeting therapies in human prostate tumours. The identification and functional assessment of these biomarkers will identify those that can be used as surrogate endpoints in clinical trials, facilitate earlier approval of investigational agents and lead to improved options for therapeutic management of prostate cancer.Read moreRead less
Investigation Of A Tumour Enzyme As A Predictor Of Patient Response To An Australian Anti-cancer Drug
Funder
National Health and Medical Research Council
Funding Amount
$362,082.00
Summary
GSAO is a new cancer drug we have developed that is currently being trialed in cancer patients. Our investigation of how GSAO works has revealed that it needs to be activated by an enzyme expressed by certain types of cancers. This finding implies that GSAO should be more effective against cancers that make this enzyme. Our aim is to establish this concept in laboratory based experiments as a basis for selection of patients who are more likely to benefit from GSAO treatment.
Therapeutic Targeting Of Precancerous Stem Cells In T Cell Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$674,737.00
Summary
We have recently identified a stem cell population causes T cell leukaemia. These cells may also survive conventional leukaemia therapies and cause relapse. This project will determine whether these stem cells can be killed using conventional leukaemia therapeutics. In addition, we will identify new therapeutic targets to eliminate these cells. This will enable us to specifically target the cells responsible for leukaemia relapse.
Drug Resistance In DNA Repair Defective Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.
Development Of A Novel MicroRNA Mimic For Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$534,179.00
Summary
Liver cancer is a major health burden globally, with a very poor prognosis. New treatments are urgently needed. We have developed proof-of-concept data showing that a tiny RNA, called a microRNA, is a powerful inhibitor of liver cancer growth. We will use this grant application to further develop the microRNA with novel chemistry so that it can be readily translated into early phase clinical trials in the near future.
Utilising Circulating Tumour DNA (ctDNA) To Optimise The Adjuvant Therapy And Follow-up Of Patients With Locally Advanced Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,316,682.00
Summary
The management of patients after surgery for rectal cancer presents multilpe dilemmas; what treatment should be given and to which patients? Our initial studies in colorectal cancer patients demonstrate that a novel blood biomarker (circulating tumour DNA) can accurately predict patient risk of recurrence and with serial samples, can indicate whether chemotherapy is being effective. During follow-up changes in this biomarker promise to be a specific and very early indicator of cancer recurrence.
Development Of Systemic Therapies To Improve Response And Prevent Resistance In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
This program of research utilises the unique resources at Melanoma Institute Australia (MIA) to understand the biology of prolonged response and resistance to novel drug therapies used in metastatic melanoma, a cancer that now leads the field in the discovery of new targets for therapeutic manipulation. This program also aims to create new methods to efficiently test and develop drug therapy combinations in humans to improve patient outcomes further or prevent metastatic melanoma altogether.
Systems Analyses Of Prostate Cancer Organoid Cultures For Precision Medicine
Funder
National Health and Medical Research Council
Funding Amount
$430,766.00
Summary
During this fellowship a research platform will be established that can efficiently predict new treatment combinations for prostate cancer. To do this, computational analyses of patient prostate cancer “organoid” cultures subjected to a panel of therapeutic drugs will be performed, to predict effective treatment combinations for any tumour of interest. Accordingly, this work will establish a foundation to decipher successful treatment regimes on an individual patient basis.
Targeting Histone Deacetylases For The Therapy Of Myc-induced Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$356,513.00
Summary
Neuroblastoma is the commonest solid tumour in early childhood. Pancreatic cancer is the fourth leading cause of cancer death in adults. In this application, we will define how proteins called histone deacetylases promote cancer initiation and progression, and whether combination therapy with an inhibitor of the histone deacetylases and another anti-cancer agent exert efficient synergistic anti-cancer effects in animal models of neuroblastoma and pancreatic cancer.